General discussion, page-3448

Massive year ahead for IHL.

OSA, patient recruitment underway at the Alfred Hospital and pending phase 2b clinical trials. Previous anecdotal observations and studies demonstrate efficacy and a positive in-human result would represent the only pharmaceutical option in this multi billion sector dominated by CPAP (Resmed).

TBI, incredible pre-clinical results to date in a sector with increasing pressure to provide a solution. Contact sports clearly the leading opportunity followed by other concussion events, motor vehicle accidents etc.

ARDS, synergistic efficacy proven and now moving the clinical program forward rapidly commencing with an application for a pre-IND meeting with the FDA. A multi billion dollar unmet need.

Psilocybin, GAD clinical trial is the first cab off the rank and IHL now the only ASX listed psychedelics company. Dr Paul Liknaitzky is already recruiting researchers and after investigating the sector IMO it’s one of the greatest opportunities I’ve seen for a while. Compass Pathways showing a clean pair of heels with a US $1.98 billion market cap.

Four standout opportunities in one company with the cash, expertise and corporate finesse to deliver.